Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oraxol PK study in breast cancer
NCT03165955Phase 1Completed
- Sponsor
- Health Hope Pharma
- Start
- May 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel + encequidar in breast cancer, sponsored by Health Hope Pharma. Primary endpoints: PK Parameters for paclitaxel_AUC (0-52) at Week 4, PK Parameters for paclitaxel_Cmax at Week 4 and 2 more. Started May 2017; status: completed.
02
Drugs
paclitaxel + encequidar
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03165955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165955.